Ablatus Therapeutics innovative cancer ablation surgery device

Dr David Brooks-Founder & CEO of Ablatus Therapeutics

  Ablatus Therapeutics, a medical device company, was initially developed by Norfolk and Norwich University hospital clinicians to improve radiofrequency ablation technology. Ablatus recently received £1 million investment from NVM private equity to continue commercialisation of their patented bimodal electric tissue ablation technology. Ablatus are now Cambridge-based and are moving towards gaining CE-mark status with this latest investment and can revolutionise cancer treatment for the masses.  
Ablatus’ tissue ablation technology is exciting, as it is a novel bimodal electric tissue ablation technology, and can address some problems of older-ablation systems. Ablation involves using a needle-like probe, with radio frequency waves passing through it, being inserted into a tumour. This destroys the tumour by increasing the temperature within the tumour tissue. This new improved method by Ablatus’ reduces the amount of tissue charring and damage done by using both AC and DC power. The Ablatus technology could burn away a tumour and cause minimal damage to a potential patient. It can also be used precisely to treat larger more difficult to get to tumours, expanding the pool of people that can be treated whilst yielding better results. This new technology could pioneer cancer treatment and surgery in our hospitals.   Other good news for Ablatus, they were recently listed as one of the top ten health innovations that could soon be on the NHS. Others to make the top ten included the conception of three parent babies, preventing genetic incurable inherited diseases and a skin cancer app the Happy Sun App, to reduce risk of melanoma. This was all part of the spotlight on the NHS turning 70 years old recently. Ablatus came in 7th place, and rightfully so.  


Ablatus hope to begin clinical trials in the next couple of years, and hope their technology will be used in the clinic in 2020. This is a rapid rise to success if the clinical trials go well, as the company was only formed in 2016. This success may be owed partly to support from the MedTech Accelerator and Health Enterprise East.




To find out more about Health Enterprise East visit their website here

To find out more about Biosensors and Diagnostics click to read the GoBio report below.


Biosensors and Diagnostics GoBio report